| FIALA, Ondřej, Miloš PEŠEK, Jindřich FÍNEK, Jana KREJČÍ, Jan ŘÍČAŘ, Zbyněk BORTLÍČEK, Lucie BENEŠOVÁ a Marek MINÁRIK. Skin Rash as Useful Marker of Erlotinib Efficacy in NSCLC and Its Impact on Clinical Practice. Neoplasma. Bratislava: Slovenská akademie věd, 2013, roč. 60, č. 1, s. 26-32. ISSN 0028-2685. doi:10.4149/neo_2013_004. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1085695,
author = {Fiala, Ondřej and Pešek, Miloš and Fínek, Jindřich and Krejčí, Jana and Říčař, Jan and Bortlíček, Zbyněk and Benešová, Lucie and Minárik, Marek},
article_location = {Bratislava},
article_number = {1},
doi = {http://dx.doi.org/10.4149/neo_2013_004},
keywords = {erlotinib; NSCLC; rash; targeted traetment; skin toxicity},
language = {eng},
issn = {0028-2685},
journal = {Neoplasma},
title = {Skin Rash as Useful Marker of Erlotinib Efficacy in NSCLC and Its Impact on Clinical Practice},
volume = {60},
year = {2013}
}
TY - JOUR
ID - 1085695
AU - Fiala, Ondřej - Pešek, Miloš - Fínek, Jindřich - Krejčí, Jana - Říčař, Jan - Bortlíček, Zbyněk - Benešová, Lucie - Minárik, Marek
PY - 2013
TI - Skin Rash as Useful Marker of Erlotinib Efficacy in NSCLC and Its Impact on Clinical Practice
JF - Neoplasma
VL - 60
IS - 1
SP - 26-32
EP - 26-32
PB - Slovenská akademie věd
SN - 00282685
KW - erlotinib
KW - NSCLC
KW - rash
KW - targeted traetment
KW - skin toxicity
N2 - Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor used in treatment of advanced NSCLC. Patients harboring EGFR or KRAS mutations represent minority of all patients in caucasian population and there is no available predictor for a predominant group of patients harboring the wild-type EGFR and wild-type KRAS genes. Skin rash is the most frequent manifestation of cutaneous toxicity of erlotinib. Rash is associated with a good therapeutic response. We aimed at the evaluation of rash as a predictor of therapeutic effect of erlotinib in patients harboring the wild-type EGFR and KRAS wild-type genes and to assess its possible usage in a clinical practice.
ER -
FIALA, Ondřej, Miloš PEŠEK, Jindřich FÍNEK, Jana KREJČÍ, Jan ŘÍČAŘ, Zbyněk BORTLÍČEK, Lucie BENEŠOVÁ a Marek MINÁRIK. Skin Rash as Useful Marker of Erlotinib Efficacy in NSCLC and Its Impact on Clinical Practice. \textit{Neoplasma}. Bratislava: Slovenská akademie věd, 2013, roč.~60, č.~1, s.~26-32. ISSN~0028-2685. doi:10.4149/neo\_{}2013\_{}004.
|
